Moreover, GSK-J4 treatment sensitized diffuse large B-cell lymphoma to chemotherapy drugs through the downregulation of B-cell receptor signaling and Bcl-6 (Mathur et al., 2017). The gene discussed is BCL6; the disease is diffuse large B-cell lymphoma.